<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01441232</url>
  </required_header>
  <id_info>
    <org_study_id>LX4211.1-105-DM</org_study_id>
    <secondary_id>LX4211.105</secondary_id>
    <nct_id>NCT01441232</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics</brief_title>
  <official_title>A Phase 1, Open-label, 3-period, 3-treatment, Single Dose Crossover Study to Evaluate the Pharmacodynamic Effects of LX4211 When Administered Concurrently With JANUVIA® (Sitagliptin) in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to evaluate the pharmacodynamics, safety, and tolerability of LX4211
      when administered concurrently with sitagliptin (Januvia®) in patients with Type 2 Diabetes
      Mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in gut hormones</measure>
    <time_frame>Days 1, 8, and 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose</measure>
    <time_frame>Days 1, 8, and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in postprandial glucose</measure>
    <time_frame>Days 1, 8, and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in insulin</measure>
    <time_frame>Days 1, 8, and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in peptide YY</measure>
    <time_frame>Days 1, 8, and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urinary glucose excretion</measure>
    <time_frame>Days 1, 8, and 15</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LX4211</intervention_name>
    <description>400 mg of LX4211 administered as two 200 mg tablets</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Januvia®</intervention_name>
    <description>100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet</description>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 18 to 65 years of age

          -  History of Type 2 Diabetes Mellitus for at least 3 months prior to Screening, with
             HgbA1c values of 6.5 to 10.5% and C-peptide ≥1.0 ng/mL

          -  Body mass index (BMI) ≤45 kg/sq m

          -  Willing and able to self-monitor blood glucose

          -  Able to provide written informed consent

        Exclusion Criteria:

          -  History of Type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketotic
             syndrome, or diabetes resulting from pancreatic disorder or secondary diabetes

          -  Current use of any blood glucose lowering agent other than metformin

          -  History of renal disease or clinically significant abnormal kidney function tests at
             Screening or Day -2

          -  Presence of active hepatic disease or clinically significant abnormal liver function
             tests at Screening or Day -2

          -  History of myocardial infarction, severe/unstable angina, or coronary
             revascularization procedure within 6 months of Day -2

          -  History of clinically significant cardiac arrhythmias within 1 year of Day -2

          -  Congestive heart failure and/or New York Heart Association (NYHA) class III or IV
             symptoms of heart failure

          -  Subjects with uncontrolled Stage 3 hypertension

          -  History of 2 or more emergency room visits, doctor's visits, or hospitalizations due
             to hypoglycemia within 6 months of Day -2

          -  History of alcohol or drug abuse within 12 months of Screening

          -  History of bowel resection &gt; 20 cm, any malabsorptive disorder, severe gastroparesis,
             and GI procedure for the purpose of weight loss that would slow gastric emptying

          -  History of HIV or hepatitis C

          -  Major surgery within 3 months of Day -2 or any planned surgery during the study

          -  History of any active infection within 2 weeks of Day -2

          -  History of pancreatitis

          -  History of any malignancy within the last 5 years which would affect the diagnosis or
             assessment of LX4211 or sitagliptin

          -  History of any serious adverse reaction or hypersensitivity to LX4211 or sitagliptin

          -  Presence of any clinically significant physical, laboratory, or ECG findings or any
             concurrent condition at Screening that may interfere with the study in the opinion of
             the investigator

          -  Triglycerides &gt; 1000 mg/dL at Screening or Day -2

          -  Donation or loss of &gt;400 mL of blood or blood product within 8 weeks prior to Day -2

          -  Use of any tobacco product for the duration of study participation

          -  Use of corticosteroids within 2 weeks of Day 1

          -  Use of digoxin or warfarin within 2 weeks prior to Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ikenna Ogbaa, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2011</study_first_submitted>
  <study_first_submitted_qc>September 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2011</study_first_posted>
  <last_update_submitted>January 26, 2012</last_update_submitted>
  <last_update_submitted_qc>January 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

